European Thyroid Journal

Home
United Kingdom
Bristol
European Thyroid Journal

The official journal of the European Thyroid Association, publishing basic, translational and clinical thyroidology.

The European Thyroid Journal publishes papers reporting original research in basic, translational and clinical thyroidology. Original contributions cover all aspects of the field, from molecular and cellular biology to immunology and biochemistry, from physiology to pathology, and from pediatric to adult thyroid diseases with a special focus on thyroid cancer. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research. The journal will further publish formal guidelines in the field, produced and endorsed by the European Thyroid Association.

17/02/2026

A new study by Jiao Wang et al. uses network toxicology to predict molecular initiators involved in monoethyl phthalate-induced thyroid cancer.

The full integrated analysis uncovered new insights into the potential mechanistic link between monoehyl phthalate and thyroid cancer, nominating a set of candidate genes including ESR1, SKP2, CASP8, ARNT, and CDKN1B as key mediators.

Read the research: doi.org/10.1530/ETJ-25-0198

13/02/2026

New Special Collection
Less is More: De-escalation in Thyroid Cancer Management

Our latest special collection highlights the current state, future directions, and challenges of de-escalation strategies in thyroid cancer management, helping to redefine optimal, patient‑centered care in thyroid oncology.

The Collection Editors invite high-quality reviews and original research articles addressing key aspects of this evolving field.

Topics of interest include:
- Active surveillance for low-risk papillary thyroid carcinoma
- The shift from total thyroidectomy to lobectomy for selected papillary and medullary thyroid cancers
- Reconsideration of indications for completion thyroidectomy
- Refinement of lymph node dissection strategies
- Narrowing of indications for adjuvant radioactive iodine therapy
- Development and application of minimally invasive interventions such as thermal ablation

📩 To submit a proposal or for more information, email etj@bioscientifica.com

Collection Editors: Prof. Iwao Sugitani, Prof. Dana M. Hartl, Prof. Louise Davies

10/02/2026

New research by Jinyoung Kim et al. evaluates the clinical applicability of an AI model, AI‑Thyroid, for thyroid nodules with atypia of undetermined significance (AUS) cytology.

A total of 165 thyroid nodules were analysed from patients who underwent fine‑needle aspiration across five medical institutions in Korea. In binary classification tasks, the model achieved:
♦ Sensitivity: 0.91
♦ Negative predictive value: 0.87
♦ AUC (based on estinated malignancy risk): 0.75 (95% CI: 0.68–0.83)
♦ AUC (derived from K‑TIRADS categories 2–5): 0.76 (95% CI: 0.69–0.83)

These results indicate comparable diagnostic accuracy to traditional scoring systems, suggesting that AI‑assisted ultrasound analysis could provide valuable supplementary diagnostic insight to support decision‑making, especially for small, low‑risk thyroid nodules.

🔗 Read the open‑access article: doi.org/10.1530/ETJ-25-0268

03/02/2026

Paediatric and young adult differentiated thyroid carcinoma (DTC) often presents at an advanced stage but still carries a good prognosis. While age‑related genomic differences compared with adult DTC are recognised, it remains unclear whether outcomes are primarily driven by age or tumour biology.

In a new multi‑institutional study, Sule Canberk et al. analyse 363 patients aged 0–25 years to assess the independent association between canonical somatic driver alterations and disease status at last clinical follow-up.

Read the full research: doi.org/10.1530/ETJ-25-0310

27/01/2026

New research by Jean-Guillaume Marchand et al. shows that EU‑TIRADS 4 nodules with back‑wall cystic figures (BWCF) have a lower malignancy risk than EU‑TIRADS 4 nodules without BWCF. Additionally, the study found that BWCF correlates with benign (Bethesda II) cytology, whereas indeterminate (Bethesda III–IV) cytology was more frequent when BWCF were absent.

These findings reinforce the importance of distinguishing BWCF from other hyperechoic foci to improve risk stratification and reduce unnecessary fine-needle aspirations.

Read the article: doi.org/10.1530/ETJ-25-0243

23/01/2026

How valuable is the microRNA‑based molecular test (mir‑THYpe full) in improving diagnostic accuracy and avoiding unnecessary surgeries for indeterminate thyroid nodules?

Eduarda Gregorio Arnaut Lima et al. have conducted the first external, independent, prospective, real‑world, observational, and non‑interventional validation study of this molecular classifier.

In total, 256 patients with Bethesda III/IV nodules were analysed. The study found that the mir‑THYpe full molecular test supported 95.5% of clinical decisions when negative and 89.8% when positive, reducing surgery rates by 79.5%.

Read the full research: doi.org/10.1530/ETJ-25-0105

16/01/2026

💫 Professor Hanneke van Santen is a leading paediatric endocrinologist and professor at Universiteit Utrecht (Utrecht University), highly specialised in the endocrine consequences of childhood cancer treatment and paediatric thyroid cancer.

Her research focuses on protecting healthy endocrine development in children during and after cancer therapy, with particular interest in safeguarding thyroid function to support normal growth and long‑term wellbeing.

We are delighted to have her as a Collection Editor for the European Thyroid Journal’s Special Collection: Current Approaches and Challenging Issues in Paediatric Thyroid Carcinoma.

📢 Be part of the collection and help advance the future of paediatric thyroidology: https://etj.bioscientifica.com/page/paediatric-thyroid-carcinoma%20/current-approaches-and-challenging-issues-in-paediatric-thyroid-carcinoma

13/01/2026

How valuable is BRAF V600E as an independent prognostic marker?

A new review by Garcilaso Riesco‑Eizaguirre concludes that BRAF V600E remains a cornerstone, but its optimal clinical value will be realized within a precision‑oncology framework - combined with other molecular markers (TERT promoter, SWI/SNF mutations) and transcriptomic metrics (TDS, miRNA profiles).

Read the full review: doi.org/10.1530/ETJ-25-0225

💫 This article forms part of a special collection: Novel Insights in Advanced Thyroid Carcinoma: From Mechanisms to Treatments. Collection Editors: Dr Iñigo Landa, Professor Iwao Sugitani and Professor Efisio Puxeddu

05/01/2026

A new systematic review by Natasha Dowell et al. evaluates the diagnostic accuracy of the Afirma GSC and ThyroSeq v3 molecular tests for detecting thyroid carcinoma in patients with cytologically indeterminate thyroid nodules.

The review provides a broader analysis than previous work by assessing surgically confirmed and unconfirmed cases separately and incorporating the latest published literature. The results demonstrate the value of both tests in ruling out malignancy and reducing unnecessary surgeries, supporting their use as effective tools for managing indeterminate thyroid nodules. However, with both tests showing low specificity, they remain limited in their ability to reliably rule in malignancy.

The review highlights the need for randomised controlled trials, long‑term follow‑up of unoperated nodules, and direct head‑to‑head comparisons to strengthen the evidence that guides clinical decision‑making.

Read the full article: doi.org/10.1530/ETJ-25-0296

31/12/2025

✨ As 2025 draws to a close, we want to thank our global community for supporting the European Thyroid Journal and for advancing thyroidology and patient care.

We’ve had the pleasure of publishing many innovative articles spanning basic, translational, and clinical thyroidology, across paediatric and adult thyroid diseases.

🥂 We wish you a very Happy New Year and look forward to what’s next for the field of thyroidology in 2026!

22/12/2025

A new review by Luigi Bartalena et al. compares the European Group on Graves’ orbitopathy (EUGOGO) 2021 guidelines and the American and European Thyroid Associations’ (ATA/ETA) 2022 consensus statement on the management of Graves’ orbitopathy (GO).

They found strong concordance on classification, assessment, prevention, and treatment of mild GO, moderate‑to‑severe and inactive GO, and sight‑threatening GO. The main divergence between the documents lies in guidance for the management of moderate‑to‑severe and active GO.

The review also provides considered revisions to current recommendations, incorporating the most recent additions to the literature.

📖 Read the full article: https://doi.org/10.1530/ETJ-25-0318

16/12/2025

💙 Uniting for thyroid health in Africa

After the International Round Table - Global Challenges in Thyroid Health at the International Thyroid Congress, an editorial calls for collaboration among continental thyroid societies to strengthen clinical practice & advocacy.

doi.org/10.1530/ETJ-25-0374

Address

Bristol

Website

https://etj.bioscientifica.com/

Alerts

Be the first to know and let us send you an email when European Thyroid Journal posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to European Thyroid Journal:

Shortcuts

Featured

Sylvian Care South Gloucestershire
Equinox South, Great Park Road, Bradley Stoke, BS32 4QL

Want your practice to be the top-listed Clinic in Bristol?